SLABÝ, Ondřej, Roman HRSTKA, Kateřina SOBKOVÁ, Lenka DUBSKÁ, Marek SVOBODA, Jaroslava OVESNÁ and Rostislav VYZULA. Knockdown of oncogenic microRNA-21 displays cytotoxicity in p53 wild-type colon cancer cells. In European Journal of Cancer Supplements. Volume 6, 2008. Oxford, UK: Elsevier Ltd., 2008, p. 78-78. ISSN 1359-6349.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Knockdown of oncogenic microRNA-21 displays cytotoxicity in p53 wild-type colon cancer cells
Name in Czech Knockdown of oncogenic microRNA-21 displays cytotoxicity in p53 wild-type colon cancer cells
Authors SLABÝ, Ondřej (203 Czech Republic, guarantor), Roman HRSTKA (203 Czech Republic), Kateřina SOBKOVÁ (203 Czech Republic), Lenka DUBSKÁ (203 Czech Republic), Marek SVOBODA (203 Czech Republic), Jaroslava OVESNÁ (203 Czech Republic) and Rostislav VYZULA (203 Czech Republic).
Edition Volume 6, 2008. Oxford, UK, European Journal of Cancer Supplements, p. 78-78, 1 pp. 2008.
Publisher Elsevier Ltd.
Other information
Original language English
Type of outcome Proceedings paper
Field of Study 30200 3.2 Clinical medicine
Country of publisher France
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 3.406
RIV identification code RIV/00216224:14110/08:00028238
Organization unit Faculty of Medicine
ISSN 1359-6349
UT WoS 000257919000299
Keywords in English colorectal; microRNAs
Tags colorectal, microRNAs
Tags International impact, Reviewed
Changed by Changed by: prof. RNDr. Ondřej Slabý, Ph.D., učo 42891. Changed: 30/9/2008 08:49.
Abstract
Although the number of verified human microRNAs (miRNAs) is still expanding, only few have been functionally described. However, emerging evidences suggest the involvement of altered regulation of miRNA in pathogenesis of cancers and these genes are thought to function as both tumours suppressor and oncogenes. Previous data suggest altered regulation of microRNA-21 (miR-21) expression in CRC. In our study, we examined by Real-Time PCR expression levels of microRNA-21 (miR-21) in 60 colorectal tumors and 40 paired adjacent non-tumor tissues and correlated them to selected clinicopathologic features and survival parameters. We used expression of U6 small nuclear RNA (RNU6B) for data normalization and standard ddCt method for relative quantification of miRNA expression. Levels of miR-21 were significantly higher in tumors comparing to normal mucosa (p < 0,0001, Wilcoxon matched-pairs test). High expression levels of miR-21 in tumors (based on high tertile) were associated also with a poor survival (long-rank p=0,043). Up-regulation of miR-21 was previously associated with high potential of invasion, intravasation and metastasis in pre-clinical colorectal cancer models. Till now no data exist focused on miR-21 effects on CRC cells proliferation. To elucidate potential involvement of miR-21 in regulation of colon cancer cells (DLD1, SW837, HCT116 wt-p53, HCT116 null-p53) proliferation we tested effects of synthetic 2'OMe-antisense-miR-21 (anti-miR-21) transfection (2'OMe-EGFP as control) on their growth by use of MTT test. Proliferation was not affected in a null-p53 cell line or cell lines expressing mutated p53 (DLD1, SW837). In a wild-type p53-expressing cell line we observed more than 20% decrease of cells proliferation by MTT test after transfection of anti-miR-21. Now we are testing attenuating effect of anti-miR-21 on CRC cells survival under conditions of p53-directed apoptosis induced by doxorubicin treatment. Simultaneously, we are evaluating also changes in invasive properties of anti-miR-21 transfected cancer cells by matrigel invasion assay. Our results suggest possible role of miR-21 in colorectal cancer pathogenesis. Supported by IGA MZ CR NR/9076-4 and project MZ0MOU2005
Abstract (in Czech)
Although the number of verified human microRNAs (miRNAs) is still expanding, only few have been functionally described. However, emerging evidences suggest the involvement of altered regulation of miRNA in pathogenesis of cancers and these genes are thought to function as both tumours suppressor and oncogenes. Previous data suggest altered regulation of microRNA-21 (miR-21) expression in CRC. In our study, we examined by Real-Time PCR expression levels of microRNA-21 (miR-21) in 60 colorectal tumors and 40 paired adjacent non-tumor tissues and correlated them to selected clinicopathologic features and survival parameters. We used expression of U6 small nuclear RNA (RNU6B) for data normalization and standard ddCt method for relative quantification of miRNA expression. Levels of miR-21 were significantly higher in tumors comparing to normal mucosa (p < 0,0001, Wilcoxon matched-pairs test). High expression levels of miR-21 in tumors (based on high tertile) were associated also with a poor survival (long-rank p=0,043). Up-regulation of miR-21 was previously associated with high potential of invasion, intravasation and metastasis in pre-clinical colorectal cancer models. Till now no data exist focused on miR-21 effects on CRC cells proliferation. To elucidate potential involvement of miR-21 in regulation of colon cancer cells (DLD1, SW837, HCT116 wt-p53, HCT116 null-p53) proliferation we tested effects of synthetic 2'OMe-antisense-miR-21 (anti-miR-21) transfection (2'OMe-EGFP as control) on their growth by use of MTT test. Proliferation was not affected in a null-p53 cell line or cell lines expressing mutated p53 (DLD1, SW837). In a wild-type p53-expressing cell line we observed more than 20% decrease of cells proliferation by MTT test after transfection of anti-miR-21. Now we are testing attenuating effect of anti-miR-21 on CRC cells survival under conditions of p53-directed apoptosis induced by doxorubicin treatment. Simultaneously, we are evaluating also changes in invasive properties of anti-miR-21 transfected cancer cells by matrigel invasion assay. Our results suggest possible role of miR-21 in colorectal cancer pathogenesis. Supported by IGA MZ CR NR/9076-4 and project MZ0MOU2005
Links
NR9076, research and development projectName: Genomické profilování v predikci odpovědi na chemoradioterapii u pacientů s lokálně pokročilým karcinomem konečníku
PrintDisplayed: 20/7/2024 04:16